[Arteriosclerosis obliterans(ASO) in diabetic patients].
Tanaka Y.
Nihon Rinsho. 2003 Jul;61(7):1187-93.
[Peripheral arteriosclerosis obliterans].
Langer B.
Rev Paul Med. 1990 Sep-Oct;108(5):195-9.
[Arteriosclerosis obliterans (ASO)].
Koshikawa M, Ikeda U.
Nihon Rinsho. 2010 May;68(5):926-9.
MicroRNA-133a in the Development of Arteriosclerosis Obliterans.
Ono K.
J Atheroscler Thromb. 2015;22(4):342-3. doi: 10.5551/jat.ED006. Epub 2015 Feb 27.
Arteriosclerosis obliterans. Diagnostic and nonoperative treatment options.
Ku A, Nagler W.
Postgrad Med. 1995 Nov;98(5):203-4, 207-10, 212.
Functional interaction between immune checkpoints and lipid metabolism in the development of arteriosclerosis obliterans.
Zhang J, Cui L, Meng X, Luo Y, Ou J, Wang S, Qiu M.
Front Immunol. 2025 Sep 1;16:1665454. doi: 10.3389/fimmu.2025.1665454. eCollection 2025.
Arteriosclerosis obliterans.
DEDICHEN J.
Bibl Cardiol. 1958;8:55-8.
Arteriosclerosis obliterans.
JUERGENS JL, FAIRBAIRN JF 2nd.
Heart Bull. 1959 Mar-Apr;8(2):22-4.
Arteriosclerosis obliterans.
WILLIAMSON P.
Am Pract Dig Treat. 1956 Apr;7(4):574-8.
[Standardize the endovascular treatment for arteriosclerosis obliterans].
Wang SM, Yao C.
Zhonghua Wai Ke Za Zhi. 2016 Aug 1;54(8):564-7. doi: 10.3760/cma.j.issn.0529-5815.2016.08.002.
